MARC Record from marc_columbia

LEADER: 05691cam a2200721Ii 4500
001 15288718
005 20210607150617.0
006 m o d
007 cr |||||||||||
008 200721s2021 si a go 000 0 eng d
035 $a(OCoLC)on1196195768
035 $a(NNC)15288718
040 $aUKAHL$beng$erda$cUKAHL$dEBLCP$dYDX$dNLW$dN$T$dYDXIT$dOCLCO$dTYFRS
019 $a1191133132$a1193128940$a1203591869$a1226504616
020 $a9781003045410$qelectronic book
020 $a1003045413$qelectronic book
020 $a9781000067385$qelectronic book
020 $a1000067386$qelectronic book
020 $a9781000067408$q(EPUB)
020 $a1000067408$q(EPUB)
020 $a9781000067392$q(electronic bk. : Mobipocket)
020 $a1000067394$q(electronic bk. : Mobipocket)
020 $z981487714X
020 $z9789814877145
024 7 $a10.1201/9781003045410$2doi
035 $a(OCoLC)1196195768$z(OCoLC)1191133132$z(OCoLC)1193128940$z(OCoLC)1203591869$z(OCoLC)1226504616
037 $a9781000067408$bIngram Content Group
037 $a9781003045410$bTaylor & Francis
050 4 $aTP248.65.E59$bP43 2021
072 7 $aMED$x072000$2bisacsh
072 7 $aSCI$x010000$2bisacsh
072 7 $aSCI$x013000$2bisacsh
072 7 $aMQP$2bicssc
082 04 $a660.6/34$223
049 $aZCUA
245 00 $aPharmaceutical Biocatalysis :$bDrugs, Genetic Diseases, and Epigenetics /$cedited by Peter Grunwald.
264 1 $aSingapore :$bJenny Stanford Publishing,$c[2021]
300 $a1 online resource :$billustrations (some color)
336 $atext$2rdacontent
337 $acomputer$2rdamedia
338 $aonline resource$2rdacarrier
490 1 $aJenny Stanford Series on Biocatalysis ;$vvolume 7
505 0 $aCover -- Half Title -- Title Page -- Copyright Page -- Table of Contents -- Preface -- Chapter 1: Fermentative Production of Vitamin B6 -- 1.1: Introduction -- 1.2: De novo Synthesis of Vitamin B6 -- 1.3: Control of Vitamin B6 Homeostasis -- 1.4: Engineering Microorganisms for the Production of B6 Vitamers -- 1.5: Novel Routes for Vitamin B6 Biosynthesis and Production -- 1.6: Rational Design and Construction of a Vitamin B6-Producing Bacterium -- 1.7: Alternative Approaches for Enhancing Vitamin B6 Production -- 1.8: Conclusions
505 8 $aChapter 4: Microbial Biotransformations in the Production and Degradation of Fluorinated Pharmaceuticals -- 4.1: Introduction -- 4.2: Fluorinated Natural Products -- 4.3: Production of Fluorinated Antibiotics in Microorganisms -- 4.4: Biological Production of [18F]-Labelled Compounds for PET Analysis -- 4.5: Microorganisms that Enable Fluorinated Drug Design -- 4.6: Production of Fluorinated Drug Metabolites in Microorganisms -- 4.7: Microbial Degradation of Fluorinated Drugs -- 4.8: Future Prospects and Challenges
506 1 $aLegal Deposit;$cOnly available on premises controlled by the deposit library and to one user at any one time;$eThe Legal Deposit Libraries (Non-Print Works) Regulations (UK).$5WlAbNL
588 $aDescription based on online resource; title from digital title page (viewed on January 28, 2021).
520 $aVolume 7 of the Jenny Stanford Series on Biocatalysis deals with several different aspects of pharmaceuticals, which include not only various applications of drugs and their metabolism but also natural resources for active pharmaceutical ingredients as well as the removal of pharmaceutical pollution. In detail, novel approaches for developing microbial fermentation processes to produce vitamin B6 using microorganisms are described together with novel routes for vitamin B6 biosynthesis. The other topics discussed are new approaches for producing the successful anticancer drug Taxol from naturally occurring precursors, molecular farming through plant engineering as a cost-effective means to produce therapeutic and prophylactic proteins, and successful screening of potent microorganisms producing L-asparaginase for various chemotherapeutic applications. Furthermore, microbial biotransformations in the production and degradation of fluorinated pharmaceuticals are described. The other chapters inform the reader about the biotransformation of xenobiotics/drugs in living systems, the degradation of pharmaceuticals by white-rot fungi and their ligninolytic enzymes, and the removal of pharmaceutical pollution from municipal sewage using laccase.
545 0 $aPeter Grunwald studied chemistry at the Universities of Saarbrücken and Hamburg, Germany. He graduated in the field of high-frequency spectroscopy and then became a staff member of the Institute of Physical Chemistry. After receiving his PhD in physical chemistry, he founded a biotechnology research group. He was appointed professor in 2001.
650 0 $aEnzymes$xIndustrial applications.
650 0 $aBiocatalysis.
650 0 $aPharmaceutical chemistry.
650 7 $aBiocatalysis.$2fast$0(OCoLC)fst01896571
650 7 $aEnzymes$xIndustrial applications.$2fast$0(OCoLC)fst00913615
650 7 $aPharmaceutical chemistry.$2fast$0(OCoLC)fst01060115
650 7 $aMEDICAL / Pharmacy$2bisacsh
650 7 $aSCIENCE / Biotechnology$2bisacsh
650 7 $aSCIENCE / Chemistry / General$2bisacsh
655 4 $aElectronic books.
700 1 $aGrunwald, Peter,$d1941-$eeditor.
776 08 $iPrint version:$aGrunwald, Peter$tPharmaceutical Biocatalysis : Drugs, Genetic Diseases, and Epigenetics$dMilton : Jenny Stanford Publishing,c2020$z9789814877145
830 0 $aJenny Stanford series on biocatalysis ;$vv. 7.
856 40 $uhttp://www.columbia.edu/cgi-bin/cul/resolve?clio15288718$zTaylor & Francis eBooks
852 8 $blweb$hEBOOKS